Just seven days after J&J formally said it was pushing away from the deal table and dropping an effort to buy Actelion, the pharma giant now has entered into “exclusive negotiations” with the Swiss biotech.
Actelion said in a statement:
There can be no assurance any transaction will result from these discussions. Actelion does not intend to make any additional comments regarding these discussions unless and until it is appropriate to do so, or a formal agreement has been reached.
While there are no guarantees, it’s likely that these two players are much closer to an understanding after lengthy discussions earlier. The latest figure on a buyout hovered around $30 billion, with a possible CVR in the mix. The CVR was from Sanofi, though, which badly needs to complete some kind of buyout after it was forced to step aside and let Pfizer acquire Medivation.
As we know, not every insider source really knows what is going on. But it looks like something definitive is brewing.
Get Endpoints News in your inbox
News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.
You're subscribing to Endpoints News
John Carroll, Editor and Co-Founder
We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.